Fujirebio (TSE: 4544) has announced that it has entered into a joint development agreement with Stem Cell Sciences. Under this agreement, the two companies will develop serum-free mediums to be used to culture and differentiate stem cells. The discovery may pave the way for the progress of regeneration medicine.
